52 results about "Staphylococcus hominis" patented technology

The invention provides a kit used for staphylococcus aureus detection. The kit used for staphylococcus aureus detection contains guide RNA of a specific targeted staphylococcus aureus rpoB gene, an amplification primer pair, hydrated TwistAmp basic kit reaction drying balls, LbCas12a protein, a single-stranded DNA probe (ssDNA), Ribonuclease Inhibitor and buffer liquid. By using the kit for staphylococcus aureus detection, the detection specificity is high, and staphylococcus aureus and other staphylococcus, including staphylococcus epidermidis, staphylococcus hominis, staphylococcus warneri,staphylococcus capitis and staphylococcus haemolyticus, can be separated. Meanwhile, by using a RNA sequence for detection, elapsed time is about 1 hour, no PCR instruments are used, the equipment requirements are low, and are significantly lower than that of a traditional bacterial culture method or PCR sequencing method, and the clinical application valve is large.

The invention discloses staphylococcus hominis with broad-spectrum antibacterial activity on gram-positive drug-resistant bacteria and a screening method thereof. The staphylococcus hominis is separated from the skin of a healthy person and is colonized; the name of the staphylococcus hominis is S34-1; the staphylococcus hominis has obvious bacteriostatic effect on clinically common gram-positivedrug-resistant pathogens, but has no bacteriostatic effect on gram-negative drug-resistant bacteria. A genome of the staphylococcus hominis S34-1 is 2195430bp, and the staphylococcus hominis S34-1 contains two plasmids, namely 29577bp and 29535bp; the staphylococcus hominis S34-1 has been collected into CGMCC (China General Microbiological Culture Collection Center) on April 3rd, 2018; the collection number is CGMCC No.15552. The invention also relates to the application of the staphylococcus hominis S34-1 to preparation of gram-positive drug-resistant bacteria drugs. The staphylococcus hominis has the advantages that the bacteria strain with broad antibacterial activity on the clinically common drug-resistant pathogens is separated from the symbiosis / colonization flora of the human body,and a foundation is laid for researching of novel antimicrobial molecules with low toxicity and no harm to human body, fully-new structure, less resistance to drug and stronger pertinence.

The invention discloses a genetically engineered lysin with a function of killing staphylococcus and a preparation method. According to the preparation method, a lysin LysGH15 is subjected to genetically engineered modification to obtain a novel bacteriophage lysin LysGH15(+). The bacteriophage lysin LysGH15(+) shows stronger bactericidal activity and wider host spectrum, in comparison with a lysin before modification, can kill staphylococcus aureus, staphylococcus epidermidis, staphylococcus haemolyticus, staphylococcus hominis, staphylococcus saprophyticus, staphylococcus cohnii, fermented staphylococcus xylosus and the like, provides a potential novel medicine to prevention and treatment of diseases caused by staphylococcal infection, and has a good application value.

The invention provides a kit for detecting staphylococcus hominis. The kit comprises a guide RNA specifically targeting a staphylococcus hominis rpoB gene, amplification primer pairs, hydrated TwistAmp basic kit reaction drying balls, an LbCas12a protein, a single-stranded DNA probe (ssDNA), a Ribonuclease Inhibitor and a buffer solution. The kit is used for detecting the staphylococcus hominis, the detection specificity is high, and the staphylococcus hominis can be distinguished from other staphylococcocci including staphylococcus aureus, staphylococcus epidermidis, staphylococcus warneri, staphylococcus capitis and staphylococcus haemolyticus. The RNA sequence is used for detection, the consumed time is about 1 hour, no PCR instrument is needed, the requirements for equipment are low and significantly lower than those of a traditional bacterial culture method or PCR sequencing method, and the clinical practical value is high.

The invention provides a primer group, kit and method for identifying staphylococcus in an environment at an in-species level, and belongs to the technical field of molecular biological detection. The primer group comprises primers F1 and R1 for amplifying staphylococcus aureus, primers F2 and R2 for amplifying staphylococcus warneri, primers F3 and R3 for amplifying staphylococcus epidermidis, primers F4 and R4 for amplifying staphylococcus hominis, primers F5 and R5 for amplifying staphylococcus capitis, and primers F6 and R6 for amplifying staphylococcus haemolyticus; and the nucleotide sequences of the primers F1, R1, F2, R2, F3, R3, F4, R4, F5, R5, F6 and R6 are respectively as shown in SEQ ID No. 1 to SEQ ID No. 12. The primer group, kit and method are easy to operate and high in sensitivity, and can complete the detection of environmental staphylococcus in a short time; and the method is low in cost, can identify various staphylococcus species, and is convenient for popularization and application.

The invention provides a kit for detecting staphylococcus haemolyticus. The kit comprises guide RNA specifically targeting staphylococcus haemolyticus rpoB gene, an amplification primer pair, hydration TwistAmp basic kit reaction drying balls, LbCas12a protein, a single-chain DNA probe (ssDNA), a Ribonuclease Inhibitor and a buffer solution. When the kit is used for detecting the staphylococcus haemolyticus, high detection specificity is achieved, and the staphylococcus haemolyticus can be distinguished from other staphylococcus such as staphylococcus aureus, staphylococcus hominis, staphylococcus warneri, staphylococcus capitis and staphylococcus epidermidis. Meanwhile, when the RNA sequence is used to perform detection, detection time is about 1 hour, a PCR instrument is not needed, equipment requirements are evidently lower than those of a traditional bacterial culture method or a PCR sequencing method, and a high clinical practical value is achieved.

The invention provides primers and a detection kit for identifying various staphylococci based on a pheS gene and application of the primers and the detection kit, and belongs to the technical field of bacterial identification. The invention provides a primer group for identifying various staphylococci based on a pheS gene. The primer group comprises the following two or more primer pairs: a primer pair for specifically amplifying staphylococcus aureus, a primer pair for specifically amplifying staphylococcus warneri, a primer pair for specifically amplifying staphylococcus epidermidis, a primer pair for specifically amplifying staphylococcus hominis, a primer pair for specifically amplifying staphylococcus capitis, and a primer pair for specifically amplifying staphylococcus haemolyticus. The primer group has the characteristics of good amplification specificity, high detection sensitivity and simultaneous identification of various staphylococci. A method for detecting various staphylococci in the environment based on the primer group can realize simultaneous identification of various staphylococci, and has the characteristics of short detection time, low detection cost and an accurate and reliable detection result.

The invention relates to the technical field of medicine, and particularly discloses application of lupenyl acetate to preparation of medicine for treating and / or preventing upper respiratory infection, or preparation of virus and / or bacterium inhibiting agents. The lupenyl acetate is from natural traditional Chinese medicine plants, has small side effects, has a certain inhibition effect on rhinoviruses, influenza viruses, respiratory syncytial viruses, adenoviruses, coronaviruses, parainfluenza viruses, staphylococcus aureus, colon bacillus, dysentery bacillus, klebsiella pneumonia, staphylococcus epidermidis and staphylococcus hominis, and has a better effect on the upper respiratory infection caused by the viruses and bacteria; the novel path for treating the upper respiratory infection by using traditional Chinese medicine ingredients is provided.

The invention provides a kit for detecting staphylococcus epidermidis. The kit comprises a guide RNA specifically targeting a staphylococcus epidermidis rpoB gene, amplification primer pairs, hydratedTwistAmp basic kit reaction drying balls, an LbCas12a protein, a single-stranded DNA probe (ssDNA), a Ribonuclease Inhibitor and a buffer solution. The kit is used for detecting the staphylococcus epidermidis, the detection specificity is high, and the staphylococcus epidermidis can be distinguished from other staphylococcocci including staphylococcus aureus, staphylococcus hominis, staphylococcus warneri, staphylococcus capitis and staphylococcus haemolyticus. The RNA sequence is used for detection, the consumed time is about 1 hour, no PCR instrument is needed, the requirements for equipment are low and significantly lower than those of a traditional bacterial culture method or PCR sequencing method, and the clinical practical value is high.

The invention provides an olive leaf element derivative and a preparation method and application thereof, and belongs to the technical field of antibacterial agents. The olive leaf element derivativehas a structure shown in the formula I, wherein R is methyl or ethyl. The olive leaf element derivative is novel in structure and excellent in antibacterial performance on staphylococcus epidermidis,staphylococcus aureus, staphylococcus hominis and enterococcus faecalis.

The present invention provides a kit for detecting staphylococcus warneri. The kit comprises a guide RNA specifically targeting a staphylococcus warneri rpoB gene, an amplification primer pair, hydration TwistAmp basic kit reaction drying spheres, LbCas12a protein, a single-stranded DNA probe (ssDNA), an ribonuclease inhibitor and a buffer solution. The kit is used for detecting the staphylococcuswarneri and high in detection specificity, and can separate the staphylococcus warneri from other staphylococci, including staphylococcus aureus, staphylococcus hominis, staphylococcus epidermidis, staphylococcus capitis and staphylococcus haemolyticus. At the same time, the use of the RNA sequence for the detection takes about 1 hour, does not require a PCR instrument, has low requirements on equipment, and is significantly lower than a conventional bacterial culture method or a PCR sequencing method and large in clinical practical value.

The invention discloses a high-specific and high-sensitive detection method for tuberculosis flora. The high-specific and high-sensitive detection method includes 1), preparing reaction liquid, 2), placing the reaction liquid in a baking oven at the temperature of 63 DEG C to perform reaction for 30-60 minutes, and determining to be positive if the reaction liquid is turbid, 3), using clinical-isolated tuberculosis bacterial strain nucleic acid, clinical-isolated non-tuberculous mycobacteria nucleic acid and a plurality of nucleic acid of clinical-isolated staphylococcus capitis, staphylococcus hominis, staphylococcus epidermidis, streptococcus viridans, escherichia coli and Klebsiella to perform reaction repeatedly, and observing positive and negative natures of the nucleic acid. Through preparation of reaction liquid and design of primer sequences, the tuberculosis flora can be quickly and accurately detected and corresponding measures can be taken timely, so that incidence rate of diseases is reduced.

The invention discloses an application of a small molecule compound DK419 in preparation of a drug for resisting staphylococcus infection, and the CAS number of the small molecule compound DK419 is 2102672-22-8; the staphylococcus comprises at least one of staphylococcus aureus, staphylococcus epidermidis, staphylococcus hominis, staphylococcus capitis and staphylococcus haemolyticus. According to the technical scheme, the novel medical application of DK419 is disclosed, DK419 has the effects of inhibiting growth of staphylococcus and killing staphylococcus aureus, the antibacterial effect is better than that of first-line antibiotic vancomycin, and the bactericidal effect is equal to that of vancomycin; the DK419 has the effect of efficiently removing a biofilm; the DK419 can play a role in resisting staphylococcus aureus infection in an in-vivo skin infection model.

An active ingredient combination.

The invention relates to probes, a chip, primers and a kit for rapid detection of ophthalmic clinical microorganisms and application thereof, and belongs to the technical field of clinical microorganism detection. The probes disclosed by the invention comprise probes for detecting staphylococcus epidermidis, staphylococcus aureus, staphylococcus haemolyticus, pseudomonas aeruginosa, staphylococcus hominis, serratia marcescens, escherichia coli, bacillus subtilis and enterobacter cloacae, respectively. The invention also discloses the primers for amplifying the target strains, and the primers can be used to amplify gene sequence fragments with the intraspecific homology of the target strains > 95% and with the interspecific homology < 75%. The invention further discloses a method for synthesizing hybridization probes on the chip, a method for hybridization reaction and a method for scanning detection. The probes disclosed by the invention are high in specificity, high in positive rate of detecting microorganisms in ophthalmic clinical samples, high in accuracy and short in diagnosis time.

The invention provides a composition containing a mixture of a first phenyl-carbamoyl thiazole derivative and a second phenyl-carbamoyl thiazole derivative which are different from each other. Together with extracts of plants such as crotalaria assamica, star anise fruits, calophyllum membranaceum, schisandrae virides caulis, cycas leaves and the like, the mixture can generate synergistic antibacterial action on staphylococcus hominis, pantoea agglomerans, kocuria kristinae, serratia liquefaciens, ralstonia pickettii, peptostreptococcus anaerobius, klebsiella oxytoca, corynebacterium macginleyi, listeria monocytogens, simulation corynebacterium, clostridium perfringens, staphylococcus haemolyticus, aeromonas hydrophila, acinetobacter baumannii, streptococcus sanguis, peptostreptococcus prevotii, propionibacterium acnes, pseudomonas oryzihabitans, staphylococcus warneri, and legionella pneumophila.

To provide a composition effective for treating microbial skin infections, atopic dermatitis and the like.SOLUTION: Methods and compositions comprising hogocidin peptides (SH-lantibiotics), derivatives and variants are provided. Also provided are methods and compositions, including probiotic compositions, that utilize strains of Staphylococcus hominis and Staphylococcus epidermidis that produce hogocidin, hogocidin-like peptides, or other inhibitors of skin pathogens. Methods of treating microbial skin infections and atopic dermatitis are also provided.SELECTED DRAWING: Figure 1A-B

The present invention relates to a deodorant composition comprising an oxazolidine- or, a thiazolidine-carboxylic acid compound, a cosmetic carrier and optionally a fragrance. The invention also relates to a manufacturing process for the deodorant composition, a method of treating malodour and a method of screening deodorant actives as well as inhibiting a Staphylococcus hominis C-S ≥-lyase.

In some aspects, the present disclosure provides methods and compositions for degrading one or more plastics, such as polyethylene terephthalate, using Staphylococcus hominis.

The invention discloses a micro-ecological viable bacterium preparation with a hair growth promoting effect. Specifically, the invention provides a staphylococcus hominis biological preparation with an effect of promoting hair growth, and the staphylococcus hominis biological preparation comprises the following components in parts by weight: 0.1-15wt% of staphylococcus hominis ShC4 freeze-dried powder, 0.1-15wt% of a hair growth promoter, 0.1-15wt% of a hair growth promoter, 0.1-15wt% of a hair growth promoter, 0.1-15wt% of a hair growth promoter, and the balance of water. 80 to 96 wt% of PEG400 (polyethylene glycol 400); and 2 to 6 wt% of PEG (Polyethylene Glycol) 3350. The viable bacterium preparation disclosed by the invention is good in flowability, uniformity and stability, has a relatively good planting effect and can be used for remarkably promoting hair growth.

Embodiments of the present disclosure generally relate to a new class of daptide antibiotics and compositions that include the daptide antibiotics. Embodiments described herein also generally relate to methods of treating various diseases or medical conditions in a patient utilizing the new class of daptide antibiotics and compositions thereof. In an embodiment, a composition for treating a skin condition in a patient is provided. The composition includes a daptide comprising: a dimethylated 7V-terminus; a Dmp-modified C- terminus; a dehydrobutyrine residue positioned between the dimethylated 7V-terminus and the Dmp-modified C-terminus; at least one alanine (A) residue or at least one dehydroalanine (Dha) residue positioned between the dimethylated 7V-terminus and the Dmp-modified C- terminus; and at least one amino acid residue positioned between the dimethylated 7V-terminus and the Dmp-modified C-terminus. In another embodiment is provided a daptide bacteriocin composition that is antimicrobial against a staphylococcal skin bacteria in a patient.

The invention provides a kit for detecting staphylococcus hominis. The kit comprises a guide RNA specifically targeting a staphylococcus hominis rpoB gene, amplification primer pairs, hydrated TwistAmp basic kit reaction drying balls, an LbCas12a protein, a single-stranded DNA probe (ssDNA), a Ribonuclease Inhibitor and a buffer solution. The kit is used for detecting the staphylococcus hominis, the detection specificity is high, and the staphylococcus hominis can be distinguished from other staphylococcocci including staphylococcus aureus, staphylococcus epidermidis, staphylococcus warneri, staphylococcus capitis and staphylococcus haemolyticus. The RNA sequence is used for detection, the consumed time is about 1 hour, no PCR instrument is needed, the requirements for equipment are low and significantly lower than those of a traditional bacterial culture method or PCR sequencing method, and the clinical practical value is high.

The present invention discloses a class of small molecule compounds of nitrogen atom double-substituted aromatic rings represented by formula (I-VI), or their hydrates or pharmaceutically acceptable salts, and pharmaceutical compositions. The present invention also discloses the use of the compounds or their pharmaceutical compositions of the present invention in the preparation of antibacterial drugs. The compounds of the present invention can effectively inhibit Gram-negative bacteria (such as Escherichia coli) and Gram-positive bacteria (such as Staphylococcus aureus), and at the same time also have good antibacterial and rapid bactericidal effects on multi-drug resistant Staphylococcus aureus and Staphylococcus hominis, etc., which are difficult to treat clinically. At the same time, the compounds of the present invention also have properties such as low toxicity and not easily inducing drug resistance, and have good application prospects for treating diseases caused by bacterial infections.

The invention belongs to the technical field of medicines, and particularly relates to a composition containing orlistat and alginic acid or derivatives of alginic acid. The composition comprises orlistat, alginic acid or derivatives of alginic acid. In the composition, the mass ratio of the orlistat to alginic acid or derivatives of alginic acid is 1:(0.01-100), and the weight average molecular weight of the alginic acid or derivatives of alginic acid is 1.36 kDa-598.56 kDa. In the composition, the orlistat and alginic acid or derivatives of alginic acid have synergistic inhibitory effect oninhibition of green plum-blossom extracts on viridans streptococcus, staphylococcus hominis, haemophilus influenzae and enterococcus faecalis, and have synergistic anti-tumor cell proliferation effecton inhibition of the green plum-blossom extracts on proliferation of prostate cancer, ovarian cancer and pancreatic cancer cells.

The invention provides a kit for detecting staphylococcus haemolyticus. The kit comprises guide RNA specifically targeting staphylococcus haemolyticus rpoB gene, an amplification primer pair, hydration TwistAmp basic kit reaction drying balls, LbCas12a protein, a single-chain DNA probe (ssDNA), a Ribonuclease Inhibitor and a buffer solution. When the kit is used for detecting the staphylococcus haemolyticus, high detection specificity is achieved, and the staphylococcus haemolyticus can be distinguished from other staphylococcus such as staphylococcus aureus, staphylococcus hominis, staphylococcus warneri, staphylococcus capitis and staphylococcus epidermidis. Meanwhile, when the RNA sequence is used to perform detection, detection time is about 1 hour, a PCR instrument is not needed, equipment requirements are evidently lower than those of a traditional bacterial culture method or a PCR sequencing method, and a high clinical practical value is achieved.

The invention provides a composition of a mixture containing a first phenylaminopyrimidinyl indole derivative and phenylaminopyrimidinyl indole derivative which are different from each other. The mixture can have synergistic antibacterial effects on streptococcus parasanguis, staphylococcus cohnii, neisseria gonorrhoeae, peptostreptococcus prevotii, staphylococcus hominis, serratia liquefaciens, achromobacter xylosoxidans, mycobacterium murinum, corynebacterium macginleyi, morganella morganii, staphylococcus capitis, streptococcus sanguis, streptococcus pyogenes, peptostreptococcus anaerobius,alkali cellulase producing chryseomonas luteola, aeromonas caviae, enterobacter cloacae, micrococcus luteus, dendritic microbacterium and legionella pneumophila with extracts of plants such as broad-leaved echinops roots, stonecrop, cyrtomium rhizomes, standish's lonicera and rhizoma alocasiae macrorrhizae.

An active ingredient combination.

The present invention discloses a Staphylococcus hominis SHoFu616 strain, a screening method thereof, and an application for preparing drugs for preventing and treating atopic dermatitis. The preservation number of the Staphylococcus hominis SHoFu616 strain is CGMCC No. 26279, and the screening method thereof comprises the following steps: Step 1: Separating, purifying and culturing the collected samples to obtain a number of monoclonal colonies; Step 2: Inoculating the number of monoclonal colonies onto a plate, screening for antibacterial ability, picking out antagonistic monoclonal colonies with antibacterial ability, and performing subculture preservation; Step 3: Identifying the subculture-preserved antagonistic monoclonal colonies to finally screen out the Staphylococcus hominis SHoFu616 strain. Through identification and analysis, this strain belongs to Staphylococcus hominis, and this strain can be used to prepare drugs for antagonizing pathogenic bacteria such as Staphylococcus aureus and drugs for preventing and treating skin inflammatory diseases such as atopic dermatitis.

The invention provides a kit for detecting staphylococcus epidermidis. The kit comprises a guide RNA specifically targeting a staphylococcus epidermidis rpoB gene, amplification primer pairs, hydratedTwistAmp basic kit reaction drying balls, an LbCas12a protein, a single-stranded DNA probe (ssDNA), a Ribonuclease Inhibitor and a buffer solution. The kit is used for detecting the staphylococcus epidermidis, the detection specificity is high, and the staphylococcus epidermidis can be distinguished from other staphylococcocci including staphylococcus aureus, staphylococcus hominis, staphylococcus warneri, staphylococcus capitis and staphylococcus haemolyticus. The RNA sequence is used for detection, the consumed time is about 1 hour, no PCR instrument is needed, the requirements for equipment are low and significantly lower than those of a traditional bacterial culture method or PCR sequencing method, and the clinical practical value is high.

A freeze-dried formulation includes an antibacterial protein having killing activity specific to at least one of or all following species: Staphylococcus arlettae, Staphylococcus aureus, Staphylococcus auricularis, Staphylococcus carnosus, Staphylococcus carprae, Staphylococcus chromogenes, Staphylococcus cohnii, Staphylococcus delphini, Staphylococcus epidermidis, Staphylococcus equorum, Staphylococcus gallinarum, Staphylococcus hemolyticus, Staphylococcus hominis, Staphylococcus intermedius, Staphylococcus kloosii, Staphylococcus lentus, Staphylococcus lugdunensis, Staphylococcus muscae, Staphylococcus pasteuri, Staphylococcus saprophyticus, Staphylococcus warneri, and Staphylococcus xylosus; a poloxamer; a sugar, and an amino acid.